PTGX
Protagonist Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology · US
$143.37
+2.23%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- 30.12x
- P/E 2027E
- —
- P/E 2028E
- 63.48x
- P/S forward
- 46.16x
Trailing multiples
Trailing twelve months
- P/E TTM
- 117.70x
- PEG TTM
- —
- Price / book
- 11.02x
- Price / sales
- 32.90x
- Price / cash flow
- 70.71x
Enterprise value
- Enterprise value
- $8.5B
- EV / sales
- 30.16x
- EV / EBITDA
- 99.02x
- EV / EBIT
- 145.76x
- Market cap
- $9.3B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026